Keith Holmes

The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

Tom Monclair, Garrett M. Brodeur, Peter F. Ambros et al. · Journal of Clinical Oncology · 2008 · 1.1K citations · Full text

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8

Surgical Risk Factors in Primary Surgery for Localized Neuroblastoma: The LNESG1 Study of the European International Society of Pediatric Oncology Neuroblastoma Group

Giovanni Cecchetto, Véronique Mosseri, Bruno De Bernardi et al. · Journal of Clinical Oncology · 2005 · 208 citations

Referral patterns for specialist child and adolescent mental health services in the Republic of Ireland during the COVID-19 pandemic compared with 2019 and 2018

Fiona McNicholas, Ian Kelleher, Elma Hedderman et al. · BJPsych Open · 2021 · 207 citations · Full text